Hervé Hoppenot is recorded as Board Member at Incyte Corp (INCY) since June 14, 2023. Incyte Corp reported in an 8-K filed December 12, 2025 that Hervé Hoppenot retired as Board of Directors, effective December 10, 2025. Incyte Corp reported in an 8-K filed June 27, 2025 that Hervé Hoppenot retired as President and Chief Executive Officer, effective June 26, 2025. Incyte Corp reported in an 8-K filed June 15, 2023 that Hervé Hoppenot was appointed Director, effective June 14, 2023. The proxy statement of Incyte Corp reports total compensation of $6,380,525 for Hervé Hoppenot in fiscal 2025, including a base salary of $1,392,499. Disclosed compensation is on record for 7 fiscal years. Hervé Hoppenot has spoken on 20 earnings calls across 1 company, most recently for Incyte Corp on April 29, 2025. Incyte Corp is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Incyte Corp includes William J. Meury (CEO and Board Member), Julian C. Baker (Chairman and Board Member), Thomas Tray (Chief Accounting Officer) and 7 others.
“On December 10, 2025, Hervé Hoppenot notified Incyte Corporation (the “Company”) that he was retiring from the Company’s Board of Directors, effective immediately.”
Incyte Corp Form 8-K, filed December 12, 2025
· Read the filing
“On June 26, 2025, Incyte Corporation (the "Company") announced that Hervé Hoppenot retired as President and Chief Executive Officer of the Company effective June 26, 2025.”
“The first quarter of 2025 was very important for Incyte Corporation not only because of the good performance of the commercial portfolio, but mostly because Q1 2025 puts us on a great trajectory for long-term growth with the continuous expansion of Apteloa, the successful launch of NixTimo, and the successes of the…”
“So we delivered another strong year with 2024 total revenues growing 15% versus 2023 to reach $4.2 billion, continuing the steady growth we have delivered since 2020.”
“The third quarter of 2024 was a very positive quarter for Incyte with a good commercial performance, FDA approval of Niktimvo, and progress of our pipeline with several key data readouts for our clinical programs.”
“During the second quarter of 2024, we made significant progress across the business with strong performance on the commercial side driven by Jakafi and Opzelura, transformation of our pipeline, where we made important decisions on our clinical programs, and capital allocation, where we closed the Escient acquisition…”
“Before I get into the quarterly results, I'm pleased to share that Matteo Trotta has recently joined Incyte as General Manager of our U.S. Dermatology business unit reporting to me.”
